

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/998,250	11/30/2001	Shoukat Dedhar	KINE001CIP5	5685
24353 7	590 02/24/2003			
	FIELD & FRANCIS	EXAMINER		
200 MIDDLEF SUITE 200	FIELD RD		CHEN, SHIN LIN	
MENLO PARK, CA 94025				
,			ART UNIT	PAPER NUMBER
			1632	0
			DATE MAILED: 02/24/2003	· 8

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-90C (Rev. 07-01)

## Office Action Summary

Application No. 09/998,250 Applicant(s)

Dedhar et al.

Examiner

Shin-Lin Chen

Art Unit 1632

	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address
Period fo	· ·	
	PRTENED STATUTORY PERIOD FOR REPLY IS SET	TO EXPIRE MONTH(S) FROM
	IAILING DATE OF THIS COMMUNICATION.	no event, however, may a reply be timely filed after SIX (8) MONTHS from the
mailing o	date of this communication.	
- If NO pe		nd will expire SIX (6) MONTHS from the mailing date of this communication.
	o reply within the set or extended period for reply will, by statute, cause th ly received by the Office later than three months after the mailing date of t	
earned p	patent term adjustment. See 37 CFR 1.704(b).	The second section of the second section secti
Status		•
	Responsive to communication(s) filed on  This action is <b>FINAL</b> . $2b$ $\square$ This action	
	•	
	Since this application is in condition for allowance e closed in accordance with the practice under Ex pai	except for formal matters, prosecution as to the merits is rte Quayle, 1935 C.D. 11; 453 O.G. 213.
Dispositi	on of Claims	
4) 💢 (	Claim(s) <u>1-14</u>	is/are pending in the application.
48	a) Of the above, claim(s)	is/are withdrawn from consideration.
5) 🗌 (	Claim(s)	is/are allowed.
6) 🗆 (	Claim(s)	is/are rejected.
7) 🗌 (	Claim(s)	is/are objected to.
8) 💢	Claims <u>1-14</u>	are subject to restriction and/or election requirement.
Applicat	ion Papers	
9) 🗌 🤄	The specification is objected to by the Examiner.	
10) 🗌	The drawing(s) filed on is/are	a) $\square$ accepted or b) $\square$ objected to by the Examiner.
	Applicant may not request that any objection to the d	rawing(s) be held in abeyance. See 37 CFR 1.85(a).
11)	The proposed drawing correction filed on	is: a) $\square$ approved b) $\square$ disapproved by the Examiner.
	If approved, corrected drawings are required in reply t	to this Office action.
12)	The oath or declaration is objected to by the Exami	ner.
Priority (	under 35 U.S.C. §§ 119 and 120	
13) 🗌	Acknowledgement is made of a claim for foreign pr	riority under 35 U.S.C. § 119(a)-(d) or (f).
a) 🗆	All b)□ Some* c)□ None of:	
1	. $\square$ Certified copies of the priority documents have	e been received.
2	$\mathbb{R}. \ \square$ Certified copies of the priority documents have	e been received in Application No
	application from the International Burea	
*Se	e the attached detailed Office action for a list of the	e certified copies not received.
14) 🗌 .	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. § 119(e).
a) 📙		• •
15) 📙 .	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. §§ 120 and/or 121.
Attachme		
	ice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s)
_	ice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)
-ı [_ ını <b>o</b> ı	rmation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:

Application/Control Number: 09/998,250 Page 2

Art Unit: 1633

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-11, drawn to a method for treating inflammation comprising administering an antisense, which is a nucleic acid, integrin linked kinase (ILK) inhibitor specific to ILK, classified in class 536, subclass 24.5.
- II. Claims 1-10 and 12, drawn to a method for treating inflammation comprising administering an inhibitor of ILK that is an antibody specific to ILK, classified in class 424, subclass 130.1.
- III. Claims 1-10 and 13, drawn to a method for treating inflammation comprising administering an inhibitor of ILK that is a small organic molecule that blocks ILK catalytic or binding activity, classified in class 514, subclass 1.
- IV. Claims 1-10 and 14, drawn to a method for treating inflammation comprising administering an inhibitor of ILK that is an agent that affects ILK activity through direct or indirect modulation of PtdIns(3, 4, 5)P3 levels, classified in class 514, subclass 1.

Claims 1-10 link(s) inventions I-IV. The restriction requirement among the linked inventions is subject to the nonallowance of the linking claim(s), claims 1-10. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction

Application/Control Number: 09/998,250 Page 3

Art Unit: 1633

requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also M.E.P.. § 804.01.

2. The inventions are distinct, each from the other because of the following reasons:

Groups I-IV are distinct from each other because they are drawn to materially different methods using compositions having different chemical structure, physical properties and biological functions, and requiring separate search: antisense nucleic acids, antibodies, small organic molecules that blocks ILK catalytic or binding activity and agents that affects ILK activity through direct or indirect modulation of PtdIns(3, 4, 5)P3 levels. Those methods differ at least in method steps, reagents and doses used, schedules used, response variables, and criteria of success. They have different classifications and the search would not be coextensive. Thus, groups I-IV are patentably distinct from each other.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

Application/Control Number: 09/998,250 Page 4

Art Unit: 1633

named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shin-Lin Chen whose telephone number is (703) 305-1678. The examiner can normally be reached on Monday to Friday from 9 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds can be reached on (703) 305-4051. The fax phone number for this group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (703) 308-0196.

Shin-Lin Chen, Ph.D.

Suther